Version May 2024
Skeletal imaging: IV: 15 mCi (555 MBq); range: 10 to 20 mCi (370 to 740 MBq); maximum dose: 20 mCi (740 MBq)
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
Skeletal imaging: IV: 0.2 mCi/kg (7.4 MBq/kg); range: 0.2 to 0.35 mCi/kg (7.4 to 13 MBq/kg); recommended total minimum dose: 1 mCi (37 MBq); maximum dose: 20 mCi (740 MBq)
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
<1%, postmarketing, and/or case reports: Hypersensitivity reaction (including severe hypersensitivity reactions), injection site reaction, nausea, vomiting
There are no contraindications listed in the manufacturer’s labeling.
Concerns related to adverse effects:
• Hypersensitivity reactions: Hypersensitivity reactions, including life-threatening reactions, as well as nausea, vomiting and injection site reactions, have been reported.
• Hypocalcemia: May form complexes with cations (eg, calcium); use with caution in patients with hypocalcemia or in patients at risk to develop hypocalcemia.
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. Note: Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.
Other warnings/precautions:
• Appropriate use: Patients should be adequately hydrated prior to and after dosing; instruct patients to void frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Kit, Intravenous:
TechneScan HDP: Contents to be combined with sodium pertechnetate Tc99m injection solution (not included)
IV: For IV administration (slow IV injection). Imaging is optimal 1 to 4 hours after injection. Patients should be adequately hydrated before and after dosing; instruct patients to void immediately before imaging and frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder.
Radiopharmaceutical; use appropriate precautions for handling and disposal.
Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding, including shielded syringes, when handling.
IV: Contents of kit are used to prepare technetium Tc 99m oxidronate and are not for direct IV injection; only reconstituted technetium Tc 99m oxidronate may be administered IV. Administer as a slow IV injection. Imaging is optimal 1 to 4 hours after injection. Patients should be adequately hydrated before and after dosing; instruct patients to void immediately before imaging and frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder.
Skeletal imaging: Skeletal imaging agent to detect areas of altered osteogenesis in adult and pediatric patients.
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
None known.
There are no known significant interactions.
Pregnancy status should be evaluated prior to use in women of reproductive potential (SNM 2010).
The manufacturer recommends elective studies be conducted during the first 10 days of the menstrual cycle in women of reproductive potential.
Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).
In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (ACR-SPR 2018; Adelstein 1999; ICRP 2000; SNM 2010).
Technetium Tc 99m is present in breast milk.
Available guidelines recommend lactating women interrupt breastfeeding for a period of 4 hours after receiving technetium Tc 99m oxidronate for a bone scan (IAEA 2018). During the period of breastfeeding interruption, the manufacturer recommends substituting formula for breast milk. Alternatively, women can pump and store breast milk prior to the procedure, which can be bottle-fed (Harding 1995).
Elective diagnostic procedures should be delayed until breastfeeding has stopped (SNM 2010). Women who are breastfeeding and caring for individuals undergoing nuclear medicine procedures do not need any additional precautions (ABM [Mitchell 2019]).
Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breastfeeding cannot be made (Mountford 1989; Rubow 1994).
Hypersensitivity reactions.
Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging
Half-life elimination: Physical: ~6 hours
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
